KRAS and breast cancer: The miR-143/miR-145 cluster is known to act as a tumor suppressor, with targets recognized in both CRC (miR-143: MACC1, TLR2; miR-145: Cateninδ-1, DFF45, STAT1; miR-143 and miR-145: KLF5) and other malignancies (miR-143: KRAS—CRC, prostate cancer, pancreatic cancer; Akt—CRC, bladder cancer, HCC, glioma; Bcl2—CRC, breast cancer, ovarian cancer, bladder cancer; miR-145: VEGF—CRC, breast cancer, ovarian cancer, thyroid cancer, glioblastoma; miR-143 and miR-145: IGFIR) [10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31].